<DOC>
	<DOCNO>NCT00501254</DOCNO>
	<brief_summary>Evaluation pharmacodynamic profile ( antiaggregant profile , balance prostanoids nitric oxid ) ASA-SR ( slow-release ) formulation comparison ASA NR ( normal release ) , 150 mg , 12 month treatment .</brief_summary>
	<brief_title>Pharmacodynamic Trial , Slow Release ASA , Platelet Functionalism , Long Term Treatment Period</brief_title>
	<detailed_description>- A large clinical trial establish efficacy antiaggregant product patient ischemic cardiopathy , stroke intermittent claudication . - The acetylsalicylic acid ( ASA ) use antiaggregant substance , nevertheless , spite centenarian , last question pending regard appropriate dose , mechanisms action implicate , association oder drug , pharmaceutical fom order improve efficacy safety ASA . - Some previous study indicate slow release form ASA different behaviour platelet effect comparison plain formulation . - The aim study demonstrate best antiaggregant safety profile low dose slow release formulation long term treatment period one year .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<criteria>Previous episode myocardial infarction Previous episodes instable angina pectoris Previous coronary revascularization Significant arterial coronary disease Patients pathologies require treatment antiaggregants Patients treatment low molecular weight heparin oral anticoagulant Patients antecedent hypersensibility ASA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Slow release ASA</keyword>
	<keyword>Platelet functionalism</keyword>
	<keyword>Secondary cardiovascular prevention</keyword>
</DOC>